$ITOS
iTeos Therapeutics, Inc.

2021 Form 10-K Financial Statement

#000095017022004409 Filed on March 23, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $344.8M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $40.51M $5.730M $15.34M
YoY Change 164.05% 73.53%
% of Gross Profit
Research & Development $59.37M $9.210M $29.90M
YoY Change 98.56% 55.64%
% of Gross Profit
Depreciation & Amortization $603.0K $150.0K $540.0K
YoY Change 11.67% -67.39% -11.48%
% of Gross Profit
Operating Expenses $99.87M $14.94M $45.24M
YoY Change 120.76% 61.29%
Operating Profit $244.9M -$45.24M
YoY Change -641.34% 61.29%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.382M $40.00K -$48.00K
YoY Change -2979.17% -100.84%
Pretax Income $256.5M -$14.90M -$38.09M
YoY Change -773.31% 70.54%
Income Tax $41.94M $0.00 -$57.00K
% Of Pretax Income 16.35%
Net Earnings $214.5M -$14.90M -$38.03M
YoY Change -663.98% 69.38%
Net Earnings / Revenue 62.21%
Basic Earnings Per Share $6.10 -$2.88
Diluted Earnings Per Share $5.68 -$425.2K -$2.88
COMMON SHARES
Basic Shares Outstanding 35.18M 15.08M
Diluted Shares Outstanding 37.77M 15.08M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $848.5M $336.3M $336.3M
YoY Change 152.32% 1589.95%
Cash & Equivalents $848.5M $336.3M $336.3M
Short-Term Investments
Other Short-Term Assets $14.09M $2.900M $2.900M
YoY Change 385.72% 222.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $874.7M $339.5M $339.5M
YoY Change 157.65% 1202.13% 1200.77%
LONG-TERM ASSETS
Property, Plant & Equipment $7.401M $1.352M $1.400M
YoY Change 428.64% 1.2% 7.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $594.0K $248.0K $400.0K
YoY Change 48.5% -15.36% 0.0%
Total Long-Term Assets $9.999M $5.014M $5.100M
YoY Change 96.06% 7.41% 10.87%
TOTAL ASSETS
Total Short-Term Assets $874.7M $339.5M $339.5M
Total Long-Term Assets $9.999M $5.014M $5.100M
Total Assets $884.7M $344.6M $344.6M
YoY Change 156.74% 1020.73% 1022.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.145M $3.026M $3.000M
YoY Change 71.5% 157.75% 150.0%
Accrued Expenses $17.93M $7.486M $7.500M
YoY Change 139.03% 75.65% 74.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $304.1M $15.00M $15.00M
YoY Change 1927.49% 13.66% 13.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.77M $480.0K $6.400M
YoY Change 333.88% -0.41% 236.84%
Total Long-Term Liabilities $27.77M $480.0K $6.400M
YoY Change 333.88% -0.41% 236.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $304.1M $15.00M $15.00M
Total Long-Term Liabilities $27.77M $480.0K $6.400M
Total Liabilities $331.9M $21.36M $21.40M
YoY Change 1450.9% 41.7% 41.72%
SHAREHOLDERS EQUITY
Retained Earnings -$73.90M
YoY Change 106.04%
Common Stock $35.00K
YoY Change 3400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $552.8M $323.2M $323.2M
YoY Change
Total Liabilities & Shareholders Equity $884.7M $344.6M $344.6M
YoY Change 156.74% 1020.73% 1022.48%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income $214.5M -$14.90M -$38.03M
YoY Change -663.98% 69.38%
Depreciation, Depletion And Amortization $603.0K $150.0K $540.0K
YoY Change 11.67% -67.39% -11.48%
Cash From Operating Activities $513.1M -$5.470M -$25.18M
YoY Change -2138.21% -70.16% 8.78%
INVESTING ACTIVITIES
Capital Expenditures $1.181M -$140.0K $356.0K
YoY Change 231.74% -26.32% -50.62%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.242M -$140.0K -$377.0K
YoY Change 229.44% -54.84% -59.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.943M $655.0K
YoY Change 349.31% 542.16%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.659M 830.0K 340.3M
YoY Change -98.92% -96.32% 1410.0%
NET CHANGE
Cash From Operating Activities 513.1M -5.470M -25.18M
Cash From Investing Activities -1.242M -140.0K -377.0K
Cash From Financing Activities 3.659M 830.0K 340.3M
Net Change In Cash 512.4M -4.780M 316.5M
YoY Change 61.91% -222.56% -15432.56%
FREE CASH FLOW
Cash From Operating Activities $513.1M -$5.470M -$25.18M
Capital Expenditures $1.181M -$140.0K $356.0K
Free Cash Flow $512.0M -$5.330M -$25.53M
YoY Change -2105.17% -70.62% 6.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
281128000
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001808865
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 itos Effective Income Tax Rate Reconciliation Local Income Taxes Percent
EffectiveIncomeTaxRateReconciliationLocalIncomeTaxesPercent
CY2021 itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39401
CY2021 dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2021 dei City Area Code
CityAreaCode
339
CY2021 dei Local Phone Number
LocalPhoneNumber
217 0161
CY2021 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
ITOS
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Public Float
EntityPublicFloat
855200000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35514613
CY2021 dei Auditor Firm
AuditorFirmId
1133
CY2021 dei Auditor Name
AuditorName
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises BV/SRL
CY2021 dei Auditor Location
AuditorLocation
Zaventem, Belgium
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
848537000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
336326000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2020Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
133000
CY2021Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
524000
CY2020Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
192000
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7544000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14086000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2893000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
874713000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
339544000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1352000
CY2021Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2004000
CY2020Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
3286000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
298000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
128000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5329000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
248000
CY2021Q4 us-gaap Assets
Assets
884712000
CY2020Q4 us-gaap Assets
Assets
344558000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5145000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3026000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
17157000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7486000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
827000
CY2020Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
4486000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
280225000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
770000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
304124000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14998000
CY2021Q4 itos Grants Repayable
GrantsRepayable
6164000
CY2020Q4 itos Grants Repayable
GrantsRepayable
5883000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4571000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
480000
CY2021Q4 us-gaap Liabilities
Liabilities
331892000
CY2020Q4 us-gaap Liabilities
Liabilities
21361000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35466001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35466001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35044758
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35044758
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413180000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
396443000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1018000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
617000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
140623000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73898000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
884712000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344558000
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
344775000
CY2021 us-gaap Revenues
Revenues
344775000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59369000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29900000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40505000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15340000
CY2021 us-gaap Operating Expenses
OperatingExpenses
99874000
CY2020 us-gaap Operating Expenses
OperatingExpenses
45240000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
244901000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-45240000
CY2021 itos Grant Income
GrantIncome
10181000
CY2020 itos Grant Income
GrantIncome
5647000
CY2020 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
286000
CY2020 itos Fair Value Adjustment For Preferred Stock Tranche Rights Liability
FairValueAdjustmentForPreferredStockTrancheRightsLiability
1265000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1382000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
256464000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38090000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41943000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-57000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-38033000
CY2020 us-gaap Dividends Preferred Stock
DividendsPreferredStock
249000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
214521000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-43402000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.10
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.68
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2020 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
5175000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35181383
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15080266
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37774790
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15080266
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-38033000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1635000
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
841000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
212886000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37192000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-36088000
CY2020 itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
CY2020 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
-5120000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
181903000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
210612000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4292000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
655000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
841000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-38033000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13794000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2943000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1635000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214521000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2021 us-gaap Profit Loss
ProfitLoss
214521000
CY2020 us-gaap Profit Loss
ProfitLoss
-38033000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
603000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
535000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
13794000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4292000
CY2021 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
12000
CY2020 itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
-1265000
CY2020 itos Deferred Rent Adjustments
DeferredRentAdjustments
-35000
CY2021 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-4071000
CY2021 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
727000
CY2020 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-142000
CY2021 itos Refundable Income Taxes
RefundableIncomeTaxes
-7544000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11789000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1927000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2280000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1677000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9959000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2759000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3480000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
316464000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19990000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
181903000
CY2021 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
175000
CY2020 us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
5120000
CY2020 itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5877000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
32019000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
108000
CY2020 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
1678000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
512381000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1788000
CY2021 itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
17000000
CY2020 itos Increase Decrease In Unrecognized Tax Benefits
IncreaseDecreaseInUnrecognizedTaxBenefits
0
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
513140000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25176000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1181000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
356000
CY2021 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
61000
CY2020 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
21000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1242000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-377000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
125358000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
332000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2943000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
655000
CY2021 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
716000
CY2020 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
4046000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3659000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
340339000
CY2021 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3176000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214500000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
140600000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, as well as the related disclosures of contingent assets and liabilities. The Company bases its estimates and assumptions on historical experiences, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ materially from these estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></p>
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">As of December 31, 2021 and 2020, the Company’s cash and cash equivalents consisted primarily of cash balances held in U.S. dollars in money market funds and money market accounts and euro in accounts with European banks in excess of publicly insured limits. The Company does not believe it is subject to unusual credit risk associated with commercial banking relationships.</span>
CY2021 itos Research And Development Tax Credits Percentage
ResearchAndDevelopmentTaxCreditsPercentage
0.135
CY2020 itos Research And Development Tax Credits Percentage
ResearchAndDevelopmentTaxCreditsPercentage
0.135
CY2021 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Shorter of useful life or term of lease
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q1 itos Right To Use Assets And Lease Liabilities
RightToUseAssetsAndLeaseLiabilities
900000
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
797448000
CY2021Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
797448000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
314636000
CY2020Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
314636000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020Q1 itos Preferred Stock Tranche Rights Liability
PreferredStockTrancheRightsLiability
0
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5043000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4014000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2971000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2662000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1352000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
CY2021Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
12991000
CY2020Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
4012000
CY2021Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3884000
CY2020Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3208000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
37000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
229000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17157000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7486000
CY2021 itos Upfront Payment Received
UpfrontPaymentReceived
625000000.0
CY2021 itos Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
625000000
CY2021 itos Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
-344775000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
280225000
CY2021 us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
1500000
CY2021 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
3167000
CY2021 itos Grant Income
GrantIncome
10181000
CY2020 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
17053000
CY2021Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6164000
CY2020Q4 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
5883000
CY2020 itos Grant Income
GrantIncome
5647000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2020Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
133000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
167709
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2045416
CY2020Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4552396
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.13
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1104666
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.39
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
28031
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
27.02
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
421947
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.98
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5207084
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
167709
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5207084
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.35
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.06
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
78747
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13794000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4292000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.46
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.75
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11000000.0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3100000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
10700000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
800000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0042
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0127
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0135
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.92
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.90
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.02
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47242000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-31184000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
303706000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-6906000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
256464000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38090000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.164
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 itos Effective Income Tax Rate Reconciliation State Income Taxes Percent
EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent
-0.005
CY2020 itos Effective Income Tax Rate Reconciliation State Income Taxes Percent
EffectiveIncomeTaxRateReconciliationStateIncomeTaxesPercent
0.048
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.047
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32029000
CY2021Q4 itos Deferred Tax Assets Accrued Bonus
DeferredTaxAssetsAccruedBonus
390000
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
-60000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
408000
CY2020Q4 itos Deferred Tax Assets Accrued Bonus
DeferredTaxAssetsAccruedBonus
0
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
17000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
313000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
3000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28546000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
41535000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32496000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
26647000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.008
CY2021 itos Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense
EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense
0.001
CY2020 itos Effective Income Tax Rate Reconciliation Relating To Non Taxable Income And Non Deductible Expense
EffectiveIncomeTaxRateReconciliationRelatingToNonTaxableIncomeAndNonDeductibleExpense
0.034
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
-0.282
CY2021 itos Effective Income Tax Rate Reconciliation Net Gilti Inclusion Income
EffectiveIncomeTaxRateReconciliationNetGiltiInclusionIncome
0.152
CY2020 itos Effective Income Tax Rate Reconciliation Local Income Taxes Percent
EffectiveIncomeTaxRateReconciliationLocalIncomeTaxesPercent
-0.086
CY2021 itos Effective Income Tax Rate Unrecognized Tax Benefits
EffectiveIncomeTaxRateUnrecognizedTaxBenefits
0.066
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.009
CY2021 itos Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent
-0.014
CY2020 itos Effective Income Tax Rate Reconciliation Change In Valuation Allowance Percent
EffectiveIncomeTaxRateReconciliationChangeInValuationAllowancePercent
-0.221
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.164
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41943000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-57000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
17097000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25206000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
7884000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
6219000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1784000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
758000
CY2021Q4 itos Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1374000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1899
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
467
CY2021 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
214521000
CY2021Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
1371000
CY2020Q4 us-gaap Deferred Tax Liabilities Other Finite Lived Assets
DeferredTaxLiabilitiesOtherFiniteLivedAssets
0
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
497000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
445000
CY2021Q4 itos Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
-31000
CY2020Q4 itos Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
-22000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1899000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
467000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5400000
CY2020 itos Net Operating Loss Carry Forwards Deductible At Maximum Rate Of Corporations Taxable Income
NetOperatingLossCarryForwardsDeductibleAtMaximumRateOfCorporationsTaxableIncome
0.80
CY2017 itos Net Operating Loss Carry Forwards Deductible At Maximum Rate Of Corporations Taxable Income
NetOperatingLossCarryForwardsDeductibleAtMaximumRateOfCorporationsTaxableIncome
1
CY2021Q4 itos Net Operating Loss Available To Offset Rate For Taxable Income Limitation Under Tcja
NetOperatingLossAvailableToOffsetRateForTaxableIncomeLimitationUnderTCJA
0.80
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
100000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
52000000.0
CY2021 itos Date Expiring De Minimis Federal Future Tax Liabilities
DateExpiringDeMinimisFederalFutureTaxLiabilities
2041
CY2021 itos Date Expiring State Tax Credit Available To Reduce Future Tax Liabilities
DateExpiringStateTaxCreditAvailableToReduceFutureTaxLiabilities
2036
CY2020Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
17000000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000
CY2021Q4 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
CY2021 us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2021 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
700000
CY2020 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0476
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35181383
CY2020 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
167000000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15080266
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.10
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.88
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.68
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1418000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6243000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
902000
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.88
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
254000000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5877000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
767000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
920000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1001000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
997000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
990000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
917000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
5341000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
770000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4571000
CY2020 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-43402000
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15080266
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2593407
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37774790

Files In Submission

Name View Source Status
0000950170-22-004409-index-headers.html Edgar Link pending
0000950170-22-004409-index.html Edgar Link pending
0000950170-22-004409.txt Edgar Link pending
0000950170-22-004409-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img162342522_0.jpg Edgar Link pending
img162342522_1.jpg Edgar Link pending
img162342522_2.jpg Edgar Link pending
img242908389_0.jpg Edgar Link pending
img242908389_1.jpg Edgar Link pending
itos-20211231.htm Edgar Link pending
itos-20211231.xsd Edgar Link pending
itos-20211231_cal.xml Edgar Link unprocessable
itos-20211231_def.xml Edgar Link unprocessable
itos-20211231_htm.xml Edgar Link completed
itos-20211231_lab.xml Edgar Link unprocessable
itos-20211231_pre.xml Edgar Link unprocessable
itos-ex10_14.htm Edgar Link pending
itos-ex10_15.htm Edgar Link pending
itos-ex21_1.htm Edgar Link pending
itos-ex23_1.htm Edgar Link pending
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
itos-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending